Journal
LEUKEMIA RESEARCH
Volume 37, Issue 8, Pages 894-899Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.leukres.2013.04.007
Keywords
Myelodysplastic syndrome; Autoimmune diseases; Outcome; Hypomethylating agents; Treatment
Categories
Funding
- National Cancer Institute [CA16056]
- Szefel Foundation
- Leonard S. LuVullo Endowment for Leukemia Research
- Nancy C. Cully Endowment for Leukemia Research
- Babcock Family Endowment
- Heidi Leukemia Research Fund, Buffalo, NY
Ask authors/readers for more resources
Our objective was to recognize the association of autoimmune diseases (AD) in patients with myelodysplastic syndromes (MDS) and understand how this association could affect prognosis and management of both diseases. We describe our cohort of 10 patients and 34 patients reported in the English literature in addition to ten cohort studies. Interestingly, four cases showed improvement in AD after 5-azacitidine treatment. The mechanism(s) of the association between AD and MDS are discussed. Treatment could be targeted against AD, MDS or both, though based on recent reports, treating MDS with hypomethylating agents alone could improve the associated AD. (C) 2013 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
